Calcium or magnesium chloride salt-based composition
US12419908B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | May 15, 2025 |
| Grant date | Sep 23, 2025 |
| Priority date | — |
| Expiry date | May 15, 2045 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Hydration of a larynx and/or vicinity with a composition comprising a salt formulation (e.g., CaCl2, MgCl2, KCl and/or NaCl) can achieve prophylactic and/or therapeutic effects (e.g., cough suppression, improving voice quality, increasing pulse oxygen saturation and/or increasing mucosal vaccination effectiveness). The composition is administered as dry particles (e.g., aerosol) or as a liquid (e.g., solution, aerosol). The liquid can have a pH of 7.0 up to around 10.0, or preferably around 7.5 up to around 9.5, or more preferably around 8.0 up to around 9.0, or even more preferably 8.0 to 8.5 or most preferably around 8.0. The droplets can have a mass median aerodynamic diameter from approximately 8 μm to approximately 15 μm or from approximately 15 μm to approximately 500 μm. A therapeutic dose (e.g., 0.5 mg to 4.0 mg mass of salt) is administered in response to an indication. Such can employ an osmolitically active composition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.